Replies to post #4922 on Momenta Pharmaceuticals, Inc. (MNTA)

[min]

Out of 8 analyst the consensus for the next two quarters are 0.62 and 0.23.

The concensus analyst estimate is the midpoint of the high and low estimate so doesn't mean much where an analyst lowballs the low estimate, as is the case for the current MNTC estimate. We are about halfway through the 3rd quarter with no Teva L so it's clear that MNTA's numbers will come in near the high end.